Allocetra
Phase 1Small molecule
Allocetra is one of 79 small molecule programs targeting Psoriatic Arthritis. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPreclinical
Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Cataflam
NovartisPreclinical
Bayer Aspirin
BayerPreclinical
Enbrel
IImmunex
Preclinical
Glucophage
Boehringer IngelheimPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoarthritis2 trials
Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)
Recruiting·—·Phase 1·NCT06748651·6 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Allocetra. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EEnlivex Therapeutics Ltd.